EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Cardiovascular safety of Janus kinase inhibitors: A pharmacovigilance study from 2012–2023

Xiaoyan Zhong, Jianchun Luo, Yuexi Huang, Shurong Wang, Yilan Huang iD

PLOS One · 2025

DOI: 10.1371/journal.pone.0322849 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS One, 2025. Verfasst von Xiaoyan Zhong und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, The Affiliated Hospital, Southwest Medical University, Luzhou, China. Hauptthemen laut MEDLINE: Pharmacovigilance, Janus Kinase Inhibitors, Cardiovascular Diseases. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Janus kinase inhibitors (JAKinibs) are increasingly used for autoimmune diseases, prompting concerns about their cardiovascular safety. This study aims to assess the cardiovascular safety of JAKinibs in real-world settings. We conducted a retrospective analysis of FDA Adverse Event Reporting System (FAERS) data from the fourth quarter of 2012 to the second quarter of 2023, focusing on cardiovascular adverse events (AEs) associated with JAKinibs. We used disproportionality analysis to calculate reporting odds ratios (RORs) and identify signals of increased cardiovascular risk. This study identified 13,556 reports of cardiovascular AEs associated with JAKinibs in the FAERS database. Compared to the full database, Baricitinib exhibited significant signals for embolic and thrombotic events (ROR 025 = 5.58), ischemic heart disease (ROR 025 = 1.56), and cardiac arrhythmias (ROR 025 = 1.14). Tofacitinib was associated with the signal for hypertension (ROR 025 = 1.05), and upadacitinib was linked to embolic and thrombotic events (ROR 025 = 1.23). When compared to TNF-α inhibitors, upadacitinib, baricitinib and tofacitinib showed 7, 6, and 2 positive signals, respectively (all ROR 025 > 1). These findings highlight the need for careful cardiovascular monitoring and risk assessment for patients receiving JAKinibs, particularly those with pre-existing cardiovascular risk factors or older age.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PharmacovigilanceJanus Kinase InhibitorsCardiovascular DiseasesHumansAzetidinesRetrospective StudiesAdverse Drug Reaction Reporting SystemsPurinesPiperidinesSulfonamidesPyrazolesPyrimidinesMaleFemaleHeterocyclic Compounds, 3-RingMiddle AgedUnited StatesUnited States Food and Drug AdministrationAdult

Substanzen

Janus Kinase InhibitorsAzetidinesPurinesPiperidinesbaricitinibSulfonamidesPyrazolesPyrimidinestofacitinibHeterocyclic Compounds, 3-Ring

Autor:innen und Institutionen

  • Department of Pharmacy, The Affiliated Hospital, Southwest Medical University, Luzhou, China.
  • Department of Critical Care Medicine, The Affiliated Hospital, Southwest Medical University, Luzhou, China.

ORCID-Profile: Yilan Huang

Zitieren

APA

Zhong, X., Luo, J., Huang, Y., Wang, S., & Huang, Y. (2025). Cardiovascular safety of Janus kinase inhibitors: A pharmacovigilance study from 2012–2023. PLOS One. https://doi.org/10.1371/journal.pone.0322849

Vancouver

Zhong X, Luo J, Huang Y, Wang S, Huang Y. Cardiovascular safety of Janus kinase inhibitors: A pharmacovigilance study from 2012–2023. PLOS One. 2025. doi:10.1371/journal.pone.0322849

BibTeX
@article{Zhong2025,
  author = {Zhong, Xiaoyan and Luo, Jianchun and Huang, Yuexi and Wang, Shurong and Huang, Yilan},
  title = {Cardiovascular safety of Janus kinase inhibitors: A pharmacovigilance study from 2012–2023},
  journal = {PLOS One},
  year = {2025},
  doi = {10.1371/journal.pone.0322849}
}
Kostenlos starten →